Gastric Cancer

Evidence-based overview of aspirin in gastric cancer, including inflammation-related rationale, GI relevance, and current evidence limits

Aspirin is biologically relevant in gastric cancer for a simple reason.

This cancer often grows out of long-standing inflammation.

That is especially true when Helicobacter pylori is part of the story.

Aspirin intersects with that biology at several levels.

It affects COX-2, inflammatory signalling, platelet-driven metastasis, and the TXA2 pathway. Those are all relevant in gastric disease. Read the review

The evidence is still mostly observational.

There is no Phase 3 adjuvant gastric-cancer trial yet.

That means the signal is encouraging, but not definitive.

Overview

Unlike colorectal cancer, gastric cancer does not yet have a biomarker-selected aspirin trial that settles the question.

What it does have is a strong mechanistic rationale plus repeated observational findings.

The most important modifier is H. pylori infection.

Across several populations, aspirin's apparent protective effect is strongest in people with current or prior H. pylori exposure. Read the review

That matters because gastric cancer is not one biology.

The aspirin signal looks stronger in non-cardia disease than cardia disease.

It also looks stronger in intestinal-type disease than diffuse-type disease. Read the review

The key caution is also simple.

People with gastric cancer often already have vulnerable gastric lining, prior ulcer history, or altered anatomy after surgery.

That makes aspirin decisions more individual here than in many other cancer settings.

Key human data

Population and case-control signal

The 2025 high-incidence population study is one of the most striking recent results.

In a population with very high CagA-positive H. pylori burden, regular aspirin use was linked to a 51% lower gastric-cancer risk after adjustment for confounders, with an adjusted odds ratio of 0.49. Non-aspirin NSAIDs did not show the same protection. Read the PubMed record

That matters because it suggests the signal may be more specific to aspirin than to NSAIDs as a class.

The H. pylori interaction

Several earlier studies point in the same direction.

In a Russian case-control study, the odds ratio for gastric cancer was 0.39 in H. pylori–infected aspirin users, while the association was much weaker or absent in uninfected people. Read the review

A Swedish case-control study showed a similar pattern, with an odds ratio of 0.60 in H. pylori–positive aspirin users versus 0.80 in uninfected users. Read the review

A Taiwan nationwide retrospective study also supported this interaction.

Gastric-cancer risk fell by about 50% in H. pylori–infected aspirin users, compared with a smaller reduction in uninfected users. Read the review

Taken together, that makes the infection link hard to dismiss.

Subtype matters

Meta-analyses and pooled observational work suggest aspirin is more protective in non-cardia gastric cancer than in cardia cancer. Read the review

That fits the biology.

Non-cardia disease is more tightly linked to H. pylori, chronic mucosal inflammation, and COX-2 activation.

The same pattern appears by histology.

The protective signal is usually stronger in intestinal-type gastric cancer than in diffuse-type disease. Read the review

The NHS/NHSII analysis also found that regular aspirin use was associated with lower H. pylori infection risk in women. Read the cohort paper

That does not prove aspirin eradicates infection in real patients.

It does support the idea that aspirin may influence both the inflammatory driver and the downstream cancer risk.

The H. pylori connection

H. pylori is the biggest known gastric-cancer driver worldwide.

It is thought to account for roughly three quarters of gastric-cancer cases globally. Read the AACR review

The carcinogenic path is well described:

H. pylori drives chronic mucosal inflammation
that raises COX-2 expression
COX-2 increases prostaglandin E2
that promotes proliferation, reduces apoptosis, and supports tumour development

There is also a second layer.

H. pylori can drive hypergastrinemia, which in turn upregulates COX-2 transcription through PI3K-related signalling. Read the review

That means the aspirin-sensitive axis is not just inflammation in the abstract.

It is connected directly to a well-known gastric-cancer driver.

Some in vitro work also suggests aspirin can inhibit H. pylori growth in a dose-dependent way. Read the review

That is not the same as saying aspirin is an anti-H. pylori treatment.

It does strengthen the biological plausibility.

The most interesting gastric-cancer aspirin story is not a single pathway.
It is the overlap between infection, inflammation, COX-2, PI3K, and metastasis biology.

Mechanistic relevance

COX-2 and PGE2

This is the most established gastric-cancer aspirin mechanism.

COX-2 is frequently overexpressed in gastric tumours, especially in H. pylori–associated, intestinal-type, non-cardia disease. Read the review

A 2024 gastrointestinal-cancers review reported that 81 mg/day aspirin inhibits the COX–PGE2 mechanism by about 45%, while higher-dose ibuprofen is needed to reach stronger inhibition. Read the review

That helps explain why even low-dose aspirin remains mechanistically relevant in gastric-cancer discussions.

PIK3CA and PI3K pathway biology

PIK3CA mutations occur in a minority of gastric cancers, roughly 10% to 15% in many series. Read the review

But the gastric story may be wider than mutation alone.

Because H. pylori and hypergastrinemia can push PI3K signalling upstream, some gastric tumours may have aspirin-relevant PI3K pathway pressure even without a classic PIK3CA mutation.

That makes the aspirin-PI3K connection potentially broader here than in tumour types where the pathway story depends more narrowly on mutation status.

TXA2 and platelet-supported metastasis

Gastric cancer also fits aspirin's anti-metastatic logic.

Higher TBXA2R expression has been linked to worse overall survival in pan-cancer analysis that includes gastric tumours. Read the AACR paper

The newer TXA2 → ARHGEF1 → CD8+ T-cell suppression mechanism adds a second reason to pay attention. Read the Cambridge summary

That pathway is systemic.

It may matter when gastric tumour cells enter the circulation and seed common metastatic sites such as the liver or peritoneum.

For the deeper mechanism page, see Aspirin and Thromboxane A2 (TXA2).

Gut and gastric microbial context

Another possible layer is microbiota change.

Regular aspirin use has been associated with shifts in gut microbial composition that may reduce pro-inflammatory, pro-neoplastic signalling in the gastrointestinal tract. Read the review

This is still an emerging mechanism.

But in a cancer so tied to microbial and inflammatory context, it is worth tracking.

Clinical positioning

Setting	Evidence	Position
Prevention in H. pylori-infected patients	Repeated observational and case-control signal, including up to about 51% lower risk in a high-incidence population. Read the review	Strongest current signal
Non-cardia, intestinal-type gastric cancer	Consistent supportive observational pattern across multiple populations. Read the review	Supportive, but still investigational
Cardia or diffuse-type gastric cancer	Signal is weaker or absent in many studies. Read the review	Not supported on current evidence
After H. pylori eradication	Biologically plausible and observationally interesting, but no definitive trial. Read the review	Reasonable research question, not established practice
Adjuvant use after surgery or resection	No Phase 3 gastric-cancer trial exists	Investigational only
PIK3CA-mutant gastric cancer	Genomic and pathway rationale, but no dedicated trial	Biologically plausible, but unproven

An important gastric-cancer caution

This is one of the hardest cancer types in which to make casual aspirin recommendations.

The same organ at risk from the cancer is also the organ at risk from aspirin.

That means standard aspirin cautions matter even more here:

prior ulcer or bleed history
altered anatomy after partial or total gastrectomy
active gastritis or mucosal fragility
anticoagulants, steroids, or other drugs that raise bleeding risk

Any real-world aspirin discussion should involve the treating upper GI, oncology, or surgical team. Read the PubMed record

For gastric-cancer patients and survivors, the question is not only "Could aspirin help?"

The equally important question is "Is my stomach or post-surgical anatomy in a condition where aspirin is safe enough to discuss at all?"

Practical interpretation

The gastric-cancer aspirin literature is more encouraging than many people expect.

The most convincing part is not a general anti-cancer claim.

It is the repeated interaction with H. pylori, non-cardia location, and intestinal-type biology.

For many readers, the most useful questions for the care team are:

Was my cancer linked to H. pylori, and has that infection been fully treated?
Is my tumour cardia or non-cardia, and intestinal or diffuse type?
Given my surgery history and current mucosal risk, is low-dose aspirin even reasonable to discuss?
Has my tumour been tested for PIK3CA mutation or other pathway features that make aspirin more biologically interesting?

The answer is not automatic.

But this is one of the cancer types where the biological rationale is strong enough to justify a careful, well-informed clinical discussion.

References

2025 high-incidence population study — regular aspirin use and lower gastric-cancer risk in a high-H. pylori setting. Read the PubMed record
2022 review — aspirin and gastric adenocarcinoma, including the H. pylori interaction. Read the review
AACR Cancer Prevention Research review — aspirin in gastric-cancer prevention and COX/H. pylori biology. Read the review
2024 GI-cancers review — aspirin dose effects on the COX–PGE2 axis. Read the review
AACR pan-cancer analysis — TBXA2R expression and survival context in gastric cancer. Read the AACR paper
Yang et al., Nature 2025 — platelet TXA2, ARHGEF1, and immune suppression in metastasis. Read the Cambridge summary
2022 review — PIK3CA, COX-2, and feedback-loop relevance in gastric cancer. Read the review

Would you like to ask Abbey about the information shared on this page? Would you like to contribute your experience, research or ideas to this page? Perhaps you want to point out something that needs changing?

Feedback Form

This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.